Download Files:
BLU2864
$420 – $3,350
Products Details
Product Description
– BLU2864 is an orally active, highly selective, ATP-competitive PRKACA inhibitor (IC50=0.3 nM). BLU2864 shows anti-tumor activity. BLU2864 can be used in cancer and polycystic kidney disease research[1][2].
Web ID
– HY-150076
Storage Temperature
– -20°C, 3 years; 4°C, 2 years (Powder)
Shipping
– Room Temperature
Applications
– Metabolism-protein/nucleotide metabolism
Molecular Formula
– C24H19F3N4O2
References
– [1]Xiaofang Wang, et al. Protein Kinase A Downregulation Delays the Development and Progression of Polycystic Kidney Disease. J Am Soc Nephrol. 2022 Jun;33(6):1087-1104.|[2]Stefanie S. Schalm, et al. Evaluation of PRKACA as a Therapeutic Target for Fibrolamellar Carcinoma. bioRxiv 2022.01.31.477690.
CAS Number
– 2810747-89-6
Molecular Weight
– 452.43
Compound Purity
– 99.24
SMILES
– FC1=CC(C(F)F)=CC2=C1[C@H]([C@@H](O)C2)NC(C(C=C3)=CN=C3C4=C(C(C)=CN5)C5=NC=C4)=O
Clinical Information
– No Development Reported
Research Area
– Cancer; Metabolic Disease
Solubility
– 10 mM in DMSO
Target
– Others
Pathway
– Others
Product type
– Reference compound
Disclaimer: All products are for research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation.
